AORT / Artivion, Inc. - Arquivamentos da SEC, Relatório Anual, Declaração de Procuração

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ___________________________________________ ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-241709

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144 (Address of principal executive

Artivion, Inc. Conflict Minerals Report For the reporting period January 1, 2025 to December 31, 2025

Exhibit 1.01 Artivion, Inc. Conflict Minerals Report For the reporting period January 1, 2025 to December 31, 2025 Background This Conflict Minerals Report (the “Report”) of Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”) is prepared pursuant to Rule 13p-1 and Form SD (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, 2025

AMENDMENT NO.2 TO SECURITIES PURCHASE OPTION AGREEMENT

Exhibit 10.3 AMENDMENT NO.2 TO SECURITIES PURCHASE OPTION AGREEMENT This Amendment No. 2 to Securities Purchase Option Agreement (this “Amendment”), is made and executed on this the 9th day of January, 2026 (the “Effective Date”), by and among Artivion, Inc., a Delaware corporation formerly known as CryoLife, Inc. (“Buyer”), Endospan Ltd., an Israeli private limited liability company (the “Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2026 ARTIVION, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2026 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number)

SECURITIES PURCHASE OPTION AGREEMENT BY AND AMONG CRYOLIFE, INC., ENDOSPAN LTD., THE SECURITYHOLDERS LISTED ON SCHEDULE 1 HERETO, AND SHAREHOLDER REPRESENTATIVE SERVICES LLC, AS THE SECURITYHOLDER REPRESENTATIVE Dated as of September 11, 2019 TABLE O

Exhibit 10.1 SECURITIES PURCHASE OPTION AGREEMENT BY AND AMONG CRYOLIFE, INC., ENDOSPAN LTD., THE SECURITYHOLDERS LISTED ON SCHEDULE 1 HERETO, AND SHAREHOLDER REPRESENTATIVE SERVICES LLC, AS THE SECURITYHOLDER REPRESENTATIVE Dated as of September 11, 2019 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 1.1 Definitions 2 ARTICLE II BUYER LOAN 2 2.1 Buyer Loan 2 ARTICLE III BUYER OPTION AND VETO SHAR

AMENDMENT NO.1 TO SECURITIES PURCHASE OPTION AGREEMENT

Exhibit 10.2 AMENDMENT NO.1 TO SECURITIES PURCHASE OPTION AGREEMENT This Amendment No. 1 to Securities Purchase Option Agreement (this “Amendment”), is made and executed on this the 1st day of July, 2024 (the “Effective Date”), by and among Artivion, Inc., a Delaware corporation formerly known as CryoLife, Inc. (“Buyer”), Endospan Ltd., an Israeli private limited liability company (the “Company”),

Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Phone: 332-895-3222 Chief Operating Officer & [email protected] Chief Financial Officer Phone: 770-419-3355 Artivion Completes Acquisition of Endospan Ltd.

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Phone: 332-895-3222 Chief Operating Officer & [email protected] Chief Financial Officer Phone: 770-419-3355 Artivion Completes Acquisition of Endospan Ltd. ATLANTA, GA – (May 18, 2026) – Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company fo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2026 ARTIVION, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2026 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 o TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTI

AMENDMENT NO.2 TO SECURITIES PURCHASE OPTION AGREEMENT

Exhibit 10.3 AMENDMENT NO.2 TO SECURITIES PURCHASE OPTION AGREEMENT This Amendment No. 2 to Securities Purchase Option Agreement (this “Amendment”), is made and executed on this the 9th day of January, 2026 (the “Effective Date”), by and among Artivion, Inc., a Delaware corporation formerly known as CryoLife, Inc. (“Buyer”), Endospan Ltd., an Israeli private limited liability company (the “Company

AMENDMENT NO.1 TO SECURITIES PURCHASE OPTION AGREEMENT

Exhibit 10.2 AMENDMENT NO.1 TO SECURITIES PURCHASE OPTION AGREEMENT This Amendment No. 1 to Securities Purchase Option Agreement (this “Amendment”), is made and executed on this the 1st day of July, 2024 (the “Effective Date”), by and among Artivion, Inc., a Delaware corporation formerly known as CryoLife, Inc. (“Buyer”), Endospan Ltd., an Israeli private limited liability company (the “Company”),

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2026 ARTIVION, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2026 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Phone: 332-895-3222 Chief Operating Officer & [email protected] Chief Financial Officer Phone: 770-419-3355 Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan First Quarter & Recent Business Highlights: •Achie

SECURITIES PURCHASE OPTION AGREEMENT BY AND AMONG CRYOLIFE, INC., ENDOSPAN LTD., THE SECURITYHOLDERS LISTED ON SCHEDULE 1 HERETO, AND SHAREHOLDER REPRESENTATIVE SERVICES LLC, AS THE SECURITYHOLDER REPRESENTATIVE Dated as of September 11, 2019 TABLE O

Exhibit 10.1 SECURITIES PURCHASE OPTION AGREEMENT BY AND AMONG CRYOLIFE, INC., ENDOSPAN LTD., THE SECURITYHOLDERS LISTED ON SCHEDULE 1 HERETO, AND SHAREHOLDER REPRESENTATIVE SERVICES LLC, AS THE SECURITYHOLDER REPRESENTATIVE Dated as of September 11, 2019 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 1.1 Definitions 2 ARTICLE II BUYER LOAN 2 2.1 Buyer Loan 2 ARTICLE III BUYER OPTION AND VETO SHAR

ANNUAL REPORT TO SECURITY HOLDERS

2025 2025 Annual Report to Stockholders NYSE:AORT www.artivion.com1655 Roberts Boulevard, N.W. Kennesaw, GA 30144 PHONE: (770) 419-3355 FAX: (770) 429-5250 E-MAIL: [email protected] www.artivion.com FORM 10-K Included in this Annual Report to Stockholders is a copy of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including certifications by the Chief Executi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definiti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2

Artivion, Inc. 1655 Roberts Blvd. NW, Kennesaw, GA 30144

Exhibit 10.32 February 16, 2026 Marshall Stanton, M.D. 888 Boulevard of the Arts; Unit 1908 Sarasota, FL 34236 Dear Marshall, On behalf of the entire team and the Company’s Board of Directors, I would like to extend my heartfelt congratulations to you on your upcoming retirement effective March 31, 2026. Your leadership, integrity, and many contributions as Senior Vice President, Clinical Affairs

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 ARTIVION, INC. (E

SUBSIDIARIES OF ARTIVION, INC.

Exhibit 21.1 SUBSIDIARIES OF ARTIVION, INC. Subsidiary Jurisdiction Artivion Chile SpA Chile Artivion Colombia SAS Colombia Artivion Cyprus Limited Cyprus Artivion EMEA GmbH Germany Artivion France S.A.S. France Artivion Hellas Single Member Ltd. Greece Artivion Hong Kong, Limited Hong Kong Artivion India Private Limited India Artivion Italy s.r.l. Italy Artivion LATAM Holdings Spain, SLU Spain Ar

Artivion Reports Fourth Quarter and Full Year 2025 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President, Phone: 332-895-3222 Chief Operating Officer & [email protected] Chief Financial Officer Phone: 770-419-3355 Artivion Reports Fourth Quarter and Full Year 2025 Financial Results Fourth Quarter Highlights: •GAAP revenue was $116.0 million in the fourth

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2026 ARTIVION, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2026 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 o TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2025 ARTIVION, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Artivion Reports Third Quarter 2025 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Laine Morgan Chief Operating Officer & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Third Quarter 2025 Financial Results Third Quarter Highlights: •Achieved revenue of $113.4 million in the third quarter of 2025

REAL ESTATE PURCHASE AND SALE CONTRACT

Exhibit 10.1 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THIS EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED REAL ESTATE PURCHASE AND SALE CONTRACT 1.PARTIES. The names and addresses of the parties to this Contract are: a. Seller 1300 East Anderson Lane, Ltd. c/o Byram Properties, LLC [REDACTED] [REDACTED] [REDACTED] [REDACTED] b

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 26, 2025 ARTIVION, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 26, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Nu

REAL ESTATE PURCHASE AND SALE CONTRACT

Exhibit 10.2 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THIS EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED REAL ESTATE PURCHASE AND SALE CONTRACT 1.PARTIES. The names and addresses of the parties to this Contract are: a. Seller Sentinel Austin I, LLC Attn: Andrew Broeren 5940 S Rainbow Blvd Ste 400 PMB 15158 Las Vegas, Nevada 8

SECOND AMENDMENT

Exhibit 10.1 EXECUTION VERSION SECOND AMENDMENT This SECOND AMENDMENT TO CREDIT AND GUARANTY AGREEMENT, dated as of September 12, 2025 (this “Amendment Agreement”), by and among ARTIVION, INC., a Delaware corporation (the “Borrower”), the Guarantor Subsidiaries party hereto from time to time, the LENDERS party hereto listed on the signature pages hereto constituting all Lenders (including each Sec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 12, 2025 ARTIVION, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 12, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Nu

144

144 0001849615 XXXXXXXX LIVE 0000784199 ARTIVION, INC. 001-13165 1655 ROBERTS BLVD NW KENNESAW GA 30144 (770) 419-3355 MARSHALL STANTON Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 18200 801211.32 47183658 08/27/2025 NYSE Common 08/27/2025 Stock Option Exercise Issuer N 18200 08/27/2025 Cash N MARSHALL STANTON 1655 ROBERTS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2025 ARTIVION, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 ARTIVION, INC. (Exact name of registrant as specified in its charter) _____

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144 (Addr

Calculation of Filing Fee Tables FORM S-8 (Form Type) ARTIVION, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) ARTIVION, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 o TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTIV

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2025 ARTIVION, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number

Artivion Reports Second Quarter 2025 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Second Quarter 2025 Financial Results Second Quarter Highlights: •Achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 millio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 28, 2025 ARTIVION, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 28, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock ATLANTA, GA – (May 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ___________________________________________ ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-241709

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144 (Address of principal executive

Artivion, Inc. Conflict Minerals Report For the reporting period January 1, 2024 to December 31, 2024

EX-1.01 2 formsd-ex101.htm EX-1.01 Exhibit 1.01 Artivion, Inc. Conflict Minerals Report For the reporting period January 1, 2024 to December 31, 2024 Background This Conflict Minerals Report (the “Report”) of Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”) is prepared pursuant to Rule 13p-1 and Form SD (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for th

AMENDED AND RESTATED ARTIVION, INC. 2020 EQUITY AND CASH INCENTIVE PLAN SECTION 1

Exhibit 10.1 AMENDED AND RESTATED ARTIVION, INC. 2020 EQUITY AND CASH INCENTIVE PLAN SECTION 1 GENERAL 1.1 Purpose. The Amended and Restated Artivion, Inc. 2020 Equity and Cash Incentive Plan (the “Plan”) has been established by Artivion, Inc. (the “Company”)1 to (i) attract, retain, and reward persons eligible to participate in the Plan; (ii) motivate Participants (as defined in Section 1.2 below

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock ATLANTA, GA – (May 14, 2025) – Arti

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 o TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTI

Artivion Reports First Quarter 2025 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports First Quarter 2025 Financial Results First Quarter Highlights: •Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ⬜ Check the appropriate box: ⬜Preliminary Proxy Statement ⬜Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definiti

ANNUAL REPORT TO SECURITY HOLDERS

2024 2024 Annual Report to Stockholders NYSE:AORT www.artivion.com1655 Roberts Boulevard, N.W. Kennesaw, GA 30144 PHONE: (770) 419-3355 FAX: (770) 429-5250 E-MAIL: [email protected] www.artivion.com FORM 10-K Included in this Annual Report to Stockholders is a copy of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, including certifications by the Chief Executi

Subsidiaries of Artivion, Inc.

Exhibit 21.1 SUBSIDIARIES OF ARTIVION, INC. Subsidiary Jurisdiction Artivion Chile SpA Chile Artivion Colombia SAS Colombia Artivion Cyprus Limited Cyprus Artivion EMEA GmbH Germany Artivion France S.A.S. France Artivion Hellas Single Member Ltd. Greece Artivion Hong Kong, Limited Hong Kong Artivion India Private Limited India Artivion Italy s.r.l. Italy Artivion LATAM Holdings Spain, SLU Spain Ar

Description of Artivion, Inc.’s Securities under Section 12 of the Exchange Act.

Exhibit 4.2 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, Artivion, Inc., a Delaware corporation (the "Company"), had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"): Common Stock. Description of Common Stock The following descri

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 ARTIVION, INC. (E

Artivion, Inc. Insider Trading Policy

Exhibit 19.1 INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN SECURITIES As adopted on August 6, 2024 EXECUTIVE SUMMARY Insider Trading – (a)It is a violation of U.S. law for directors, officers, employees, and other individuals who possess material nonpublic information about Artivion, Inc. (together with its subsidiaries, the “Company"), or material nonpublic informa

Amendment to Exclusive Distribution Agreement, by and between JOTEC GmbH, as distributor, and Endospan Ltd., as manufacturer, dated

Exhibit 10.20(d) AMENDMENT NO. 4 TO EXCLUSIVE DISTRIBUTION AGREEMENT This Amendment No. 4 is dated July 22, 2024 (the “Amendment”), and is between Artivion, Inc. (formerly CryoLife, Inc.) located at Lotzernacker 23, 72379 Hechingen, Germany (“Distributor”) and Endospan, Ltd., located at Maskit St. 4 Herzlia Business Park, Herzlia, Israel 46733 (the “Company”). Each of Company and Distributor are s

Artivion Reports Fourth Quarter and Full Year 2024 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Fourth Quarter and Full Year 2024 Financial Results Fourth Quarter Highlights: •Achieved revenue of $97.3 million in the fourth quarter of 2024 versus

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Num

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 23, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Num

Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis

FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis ATLANTA, GA – (December 9, 2024) – Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular sur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 9, 2024 ARTIVION, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 9, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 9, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb

JOINT FILING AGREEMENT

EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Artivion, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under t

AORT / Artivion, Inc. / BlackRock, Inc. Passive Investment

SC 13G/A 1 us2289031005110824.txt us2289031005110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) ARTIVION, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 228903100 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

AORT / Artivion, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Artivion, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 228903100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165

Artivion Reports Third Quarter 2024 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Third Quarter 2024 Financial Results Third Quarter Highlights: •Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb

AORT / Artivion, Inc. / BlackRock, Inc. Passive Investment

SC 13G/A 1 us2289031005101824.txt us2289031005101824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) ARTIVION, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 228903100 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

LETTER

September 6, 2024 J. Patrick Mackin President, Chief Executive Officer and Chairman Artivion, Inc. 1655 Roberts Boulevard N.W. Kennesaw, GA 30144 Re: Artivion, Inc. Definitive Proxy Statement on Schedule 14A Filed April 1, 2024 File No. 001-13165 Dear J. Patrick Mackin: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy a

1655 Roberts Boulevard, N.W. Kennesaw, Georgia 30144

1655 Roberts Boulevard, N.W. Kennesaw, Georgia 30144 August 28, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Charlotte Young and Amanda Ravitz Re: Artivion, Inc. Definitive Proxy Statement on Schedule 14A Filed April 1, 2024 File No. 001-13165 Ladies and Gentlemen: We are submitting this letter in respon

First Amendment to Credit and Guaranty Agreement by and among Artivion, Inc., On-X Life Technologies Holdings, Inc., On-X Life Technologies, Inc., and Ascyrus Medical, LLC, as subsidiary guarantors, the lenders from time to time party thereto and Ares Capital Corporation, as administrative agent and collateral agent, dated June 13, 2024. (Incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed August 9, 2024.)

Exhibit 10.1 FIRST AMENDMENT This FIRST AMENDMENT, dated as of June 13, 2024 (this “Amendment Agreement”), to the CREDIT AND GUARANTY AGREEMENT, dated as of January 18, 2024 (the “Credit Agreement”), among ARTIVION, INC., a Delaware corporation (the “Borrower”), the Guarantor Subsidiaries party thereto from time to time, the LENDERS party thereto and ARES CAPITAL CORPORATION, as Administrative Age

Amended and Restated Loan Agreement, dated July 1, 2024, by and between Artivion, Inc., as lender, and Endospan Ltd., as borrower. (Incorporated herein by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed August 9, 2024.)

Exhibit 10.2 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION TO PROTECT PERSONAL PRIVACY Amended and Restated Loan Agreement This Amended and Restated Loan Agreement (the “Agreement”) is made and entered into as of the 1st day of July, 2024 (the “Effective Date”), by and between Artivion, Inc., a Delaware corporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTIV

LETTER

August 9, 2024 J. Patrick Mackin President, Chief Executive Officer and Chairman Artivion, Inc. 1655 Roberts Boulevard N.W. Kennesaw, GA 30144 Re: Artivion, Inc. Definitive Proxy Statement on Schedule 14A Filed April 1, 2024 File No. 001-13165 Dear J. Patrick Mackin: We have limited our review of your most recent definitive proxy statement to those issues we have addressed in our comment(s). Pleas

Artivion Reports Second Quarter 2024 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Second Quarter 2024 Financial Results Second Quarter Highlights: •Achieved revenue of $98.0 million in the second quarter of 2024 versus $89.3 million

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number

Artivion Amends Agreements with Endospan Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purchase Option Reduced to $135 million, inclusive of loan off-set, and $100 milli

FOR IMMEDIATE RELEASE Contacts: Artivion, Inc. Lance A. Berry Executive Vice President & Chief Financial Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Laine Morgan Phone: 332-895-3222 [email protected] Artivion Amends Agreements with Endospan Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purcha

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ___________________________________________ ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-241709

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144 (Address of principal executive

Artivion, Inc. Conflict Minerals Report For the reporting period January 1, 2023 to December 31, 2023

Exhibit 1.01 Artivion, Inc. Conflict Minerals Report For the reporting period January 1, 2023 to December 31, 2023 Background This Conflict Minerals Report (the “Report”) of Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”) has been prepared pursuant to Rule 13p-1 and Form SD (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1,

Amended and Restated Bylaws of Artivion, Inc., effective May 15, 2024, a Delaware Corporation (Incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed May 17, 2024.)

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ARTIVION, INC. (A DELAWARE CORPORATION) (Effective May 15, 2024) ARTICLE I OFFICES Section 1. Principal and Business Offices. The corporation may have such principal and other business offices, either within or without the State of Delaware, as the Board of Directors (the “Board”) may from time to time determine or the business of the corporation may requ

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Amended and Restated Certificate of Incorporation, effective May 15, 2024. (Incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed May 16, 2024.)

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARTIVION, INC. (Originally incorporated January 1, 2022 under the name CryoLife, Inc.) Artivion, Inc., a corporation organized and existing under the laws of the State of Delaware, DOES HEREBY CERTIFY AS FOLLOWS: 1.The name of the corporation is “Artivion, Inc.” The original certificate of incorporation was filed with the Secretary o

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTI

Artivion Reports First Quarter 2024 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports First Quarter 2024 Financial Results First Quarter Highlights: •Achieved revenue of $97.4 million in the first quarter of 2024 versus $83.2 million in

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2

PRELIMINARY PROXY STATEMENT SUBJECT TO COMPLETION DATED March 21, 2024 In accordance with Rule 14a-6(d) under Regulation 14A, please be advised that Artivion, Inc. intends to release definitive copies of this Proxy Statement to security holders on or

PRELIMINARY PROXY STATEMENT SUBJECT TO COMPLETION DATED March 21, 2024 In accordance with Rule 14a-6(d) under Regulation 14A, please be advised that Artivion, Inc.

AORT / Artivion, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment

SC 13G 1 d763985dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Artivion, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 228903100 (CUSIP Number) February 28, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropria

AGREEMENT

EX-99.1 2 d763985dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: March 11, 2024

Form of Indenture.

Exhibit 4.2 ARTIVION, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.1. Definitions 1 Section 1.2. Other Definitions 3 Section 1.3. Incorporation by Reference of Trust Indenture Act 3 Section 1.4. Rules of Construction 3 ARTICLE II. THE SECURITIES Section 2.1. Issuable in Series 4 Section 2.2. Establishment of Term

As filed with the Securities and Exchange Commission on February 29, 2024

Table of Contents  As filed with the Securities and Exchange Commission on February 29, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Artivion, Inc. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo

Summary of 2023 Compensation Arrangements with Non-Employee Directors.

Exhibit 10.6 SUMMARY OF 2023 COMPENSATION ARRANGEMENTS WITH NON-EMPLOYEE DIRECTORS (Effective as of December 31, 2023) The following summarizes the compensation and benefits received by the non-employee Directors of Artivion as of December 31, 2023. It is intended to be a summary of compensation arrangements, and in no way is intended to provide any additional rights to any non-employee Director.

Form of 2023 Performance Share Award Agreement pursuant to the 2020 Artivion, Inc. Equity and Cash Incentive Plan, adopted February 2023.

Exhibit 10.3(g) Name: Total No. of Units: ARTIVION, INC. EQUITY AND CASH INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Artivion, Inc. 2020 Equity and Cash Incentive Plan (the “Plan”) will have the same defined meanings in this Performance Share Award Agreement, including the Notice of Stock Unit Grant (the “Notice of Grant”) and the Term

(Incorporated herein by reference to Exhibit 10.27 to the Registrant's Annual Report on Form 10-K filed February 23, 2024.)

Exhibit 10.27 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION TO PROTECT PERSONAL PRIVACY December 6, 2023 Ms. Amy D. Horton [REDACTED] [REDACTED] Re: Performance and Retention Bonus Dear Amy: It is with great pleasure that I inform you that the Board of Directors of Artivion, Inc. (the “Company”) has approved, upo

Form of 2023 Restricted Stock Unit Award Agreement pursuant to the 2020 Artivion, Inc. Equity and Cash Incentive Plan, adopted August 2023.

Exhibit 10.3(j) Name: Total No. of Units: ARTIVION, INC. EQUITY AND CASH INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Artivion, Inc. Equity and Cash Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Award Agreement, including the Notice of Restricted Stock Unit Grant (the “Notice of Grant”

Third Amendment to Exclusive Distribution Agreement, by and between JOTEC GmbH, as distributor, and Endospan Ltd., as manufacturer, dated October 1, 2023.

Exhibit 10.21(c) CERTAIN INFORMATION HAS BEEN OMITTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT NO. 3 TO EXCLUSIVE DISTRIBUTION AGREEMENT This Amendment No. 3 is dated 1st October 2023 (the “Amendment”), and is between JOTEC GmbH, a wholly-owned subsidiar

Change of Control Severance Agreement, dated November 10, 2023, by and between Artivion, Inc. and Lance A. Berry.

Exhibit 10.26 ARTIVION, INC. CHANGE OF CONTROL SEVERANCE AGREEMENT This Change of Control Severance Agreement (this “Agreement”) dated as of the 4th day of December, 2023 is made and entered into by and between Artivion, Inc., a Delaware corporation (“Artivion” or the “Company”) and Lance A. Berry (the “Executive”). RECITALS 1. It is expected that the Company from time to time will consider the po

Artivion, Inc., Updated Clawback Policy, as amended August 2023.

Exhibit 97.1 ARTIVION, INC. UPDATED CLAWBACK POLICY As Amended August 2023 In the event Artivion, Inc. (the “Company”) issues a material accounting restatement of its financial statements, or issues a restatement that corrects errors that are not material to previously issued financial statements, but that would result in a material misstatement if corrected or left uncorrected in a current financ

Retirement Eligibility Letter Agreement, dated December 4, 2023, by and between Artivion, Inc. and D. Ashley Lee.

Exhibit 10.23 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION TO PROTECT PERSONAL PRIVACY CONFIDENTIAL December 4, 2023 Mr. D. Ashley Lee [REDACTED] [REDACTED] Re: Retirement Eligibility Dear Ashley: It is with great pleasure that I inform you that the Compensation Committee (the “Committee”) of the Board of Direct

Offer Letter, dated December 4, 2023, by and between Artivion, Inc. and Lance A. Berry.

Exhibit 10.25 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION TO PROTECT PERSONAL PRIVACY November 10, 2023 Via email: [REDACTED] Mr. Lance Berry [REDACTED] [REDACTED] Dear Lance: It is with great pleasure that I am writing this letter to outline our offer to you to join Artivion, Inc. (“Artivion” or the “Company”)

Form of 2023 Long Term Incentive Program Performance Share Award Agreement pursuant to the 2020 Artivion, Inc. Equity and Cash Incentive Plan, adopted February 2023.

Exhibit 10.3(f) Name: Total No. of Units: ARTIVION, INC. EQUITY AND CASH INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Artivion, Inc. 2020 Equity and Cash Incentive Plan (the “Plan”) will have the same defined meanings in this Performance Share Award Agreement, including the Notice of Stock Unit Grant (the “Notice of Grant”) and the Term

Consulting Agreement, dated January 1, 2024, by and between Artivion, Inc. and D. Ashley Lee. (Incorporated herein by reference to Exhibit 10.24 to the Registrant's Annual Report on Form 10-K filed February 23, 2024.)

Exhibit 10.24 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION TO PROTECT PERSONAL PRIVACY CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (“Agreement”) is entered into as of this 1st day of January 2024 (“Effective Date”) by and between Artivion, Inc., on its own behalf and on behalf of its affiliates (collectively,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 ARTIVION, INC. (E

Form of 2023 Restricted Stock Unit Award Agreement pursuant to the 2020 Artivion, Inc. Equity and Cash Incentive Plan, adopted February 2023.

Exhibit 10.3(h) Name: Total No. of Units: ARTIVION, INC. EQUITY AND CASH INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Artivion, Inc. Equity and Cash Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Award Agreement, including the Notice of Restricted Stock Unit Grant (the “Notice of Grant”

Subsidiaries of Artivion, Inc.

Exhibit 21.1 SUBSIDIARIES OF ARTIVION, INC. Subsidiary Jurisdiction Artivion Chile SpA Chile Artivion Colombia SAS Colombia Artivion Cyprus Limited Cyprus Artivion EMEA GmbH Germany Artivion Hellas Single Member Ltd. Greece Artivion Hong Kong, Limited Hong Kong Artivion LATAM Holdings Spain, SLU Spain Artivion Malaysia, Sdn. Bhd. Malaysia Artivion New Zealand New Zealand Artivion Polska Sp. z.o.o.

Form of 2023 Performance Share Award Agreement pursuant to the 2020 Artivion, Inc. Equity and Cash Incentive Plan, adopted August 2023.

Exhibit 10.3(i) Name: Total No. of Units: ARTIVION, INC. EQUITY AND CASH INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Artivion, Inc. 2020 Equity and Cash Incentive Plan (the “Plan”) will have the same defined meanings in this Performance Share Award Agreement, including the Notice of Stock Unit Grant (the “Notice of Grant”) and the Term

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Num

Artivion Reports Fourth Quarter and Full Year 2023 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Fourth Quarter and Full Year 2023 Financial Results Fourth Quarter and Recent Business Highlights: •Achieved revenue of $93.7 million in the fourth qu

AORT / Artivion, Inc. / MACQUARIE GROUP LTD - SC 13G/A Passive Investment

SC 13G/A 1 d748547dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Artivion Inc (Name of Issuer) Common Shares (Title of Class of Securities) 228903100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th

Page 13 of 13

EX-99.B 3 d748547dex99b.htm EX-99.B EXHIBIT B Powers of Attorney for Macquarie Group Limited incorporated by reference to 13G filings made by Macquarie Group Limited on June 7, 2023. Page 13 of 13

Page 8 of 13

EX-99.A 2 d748547dex99a.htm EX-99.A EXHIBIT A AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS AGREEMENT made this [7th] day of FEBRUARY, 2024 by and between Delaware Funds by Macquarie,® Optimum Fund Trust and Macquarie ETF Trust listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectiv

AORT / Artivion, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0340-artivioninc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Artivion Inc Title of Class of Securities: Common Stock CUSIP Number: 228903100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule p

AORT / Artivion, Inc. / MORGAN STANLEY - MS AMENDMENT Passive Investment

SC 13G/A 1 ArtivionIncAORT.txt MS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* ARTIVION, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 228903100 - (CUSIP Number) December 31, 2023 - (Date Of Event which Requires Filing of this Statement) Check the appropriate box to

AORT / Artivion, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* ARTIVION, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 228903100 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi

AORT / Artivion, Inc. / BlackRock Inc. Passive Investment

SC 13G/A 1 us2289031005012224.txt us2289031005012224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) ARTIVION, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 228903100 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 18, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Credit and Guaranty Agreement, dated as of January 18, 2024, by and among Artivion, Inc., On-X Life Technologies Holdings, Inc., On-X Life Technologies, Inc. and Ascyrus Medical, LLC, as subsidiary guarantors, the lenders from time to time party thereto and Ares Capital Corporation, as administrative agent and collateral agent.

Exhibit 10.1 EXECUTION VERSION $350,000,000 CREDIT AND GUARANTY AGREEMENT dated as of January 18, 2024 by and among ARTIVION, INC., as Borrower, CERTAIN SUBSIDIARIES OF THE BORROWER FROM TIME TO TIME PARTY HERETO, as Guarantor Subsidiaries, The Lenders From Time to Time Party Hereto, and ARES CAPITAL CORPORATION, as Administrative Agent and Collateral Agent ARES CAPITAL MANAGEMENT LLC, as Sole Lea

Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer Reaffirms Financial Guidance Provided on November 2, 2023

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President, Phone: 332-895-3222 Finance [email protected] Phone: 770-419-3355 Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer Reaffirms Financial Guidance Provided

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 6, 2023 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 o TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165

Fifth Amendment to Lease Agreement between Artivion, Inc. and 1300 E. Anderson Lane, Ltd., dated September 1, 2023. (Incorporated herein by reference to Exhibit 10.3(e) to the Registrant's Quarterly Report on Form 10-Q filed November 3, 2023.)

Exhibit 10.3(e) CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED FIFTH AMENDMENT TO LEASE AGREEMENT This FIFTH AMENDMENT TO LEASE AGREEMENT (FIFTH AMENDMENT) is made and entered into on this 11th day of September 2023 by an

Fourth Amendment to Lease Agreement between Artivion, Inc. and 1300 E. Anderson Lane, Ltd., dated March 8, 2019. (Incorporated herein by reference to Exhibit 10.3(d) to the Registrant's Quarterly Report on Form 10-Q filed November 3, 2023.)

Exhibit 10.3(d) CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED FOURTH AMENDMENT TO LEASE AGREEMENT This FOURTH AMENDMENT TO LEASE AGREEMENT (FOURTH AMENDMENT) is made between 1300 E. ANDERSON LANE, LTD., (LANDLORD), and C

INDEMNIFICATION AGREEMENT

Exhibit 10.2 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of , between ARTIVION, INC., a Delaware corporation (the “Corporation”), and , a resident of (the “Indemnitee”). W I T N E S S E T H WHEREAS, at the request of the Corporation, Indemnitee is an executive officer and/or a member of the board of directors of the Corporation (the “Boar

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2023 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Artivion Reports Third Quarter 2023 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Third Quarter 2023 Financial Results Third Quarter and Recent Business Highlights: •Achieved revenue of $87.9 million in the third quarter of 2023 versus

LETTER

United States securities and exchange commission logo August 29, 2023 J. Patrick Mackin Chairman, President, and Chief Executive Officer Artivion, Inc. 1655 Roberts Blvd., NW Kennesaw, GA 30144 Re: Artivion, Inc. Definitive Proxy Statement on Schedule 14A Filed April 3, 2023 File No. 001-13165 Dear J. Patrick Mackin: We have completed our review of your filing. We remind you that the company and i

1655 Roberts Boulevard, N.W. Kennesaw, Georgia 30144

1655 Roberts Boulevard, N.W. Kennesaw, Georgia 30144 August 18, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford and Amanda Ravitz Re: Artivion, Inc. Definitive Proxy Statement on Schedule 14A Filed April 3, 2023 File No. 001-13165 Ladies and Gentlemen: We are submitting this letter in respon

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2023 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number

to the Registrant’s Current Report on Form 8-K filed

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ARTIVION, INC. (A DELAWARE CORPORATION) (Effective September 1, 2023) ARTICLE I OFFICES Section 1. Principal and Business Offices. The corporation may have such principal and other business offices, either within or without the State of Delaware, as the Board of Directors (the “Board”) may from time to time determine or the business of the corporation may

LETTER

United States securities and exchange commission logo August 4, 2023 J. Patrick Mackin Chairman, President, and Chief Executive Officer Artivion, Inc. 1655 Roberts Blvd., NW Kennesaw, GA 30144 Re: Artivion, Inc. Definitive Proxy Statement on Schedule 14A Filed April 3, 2023 File No. 001-13165 Dear J. Patrick Mackin: We have limited our review of your most recent definitive proxy statement to those

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTIV

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 3, 2023 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number

Artivion Reports Second Quarter 2023 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Second Quarter 2023 Financial Results Second Quarter and Recent Business Highlights: •Achieved revenue of $89.3 million in the second quarter of 2023 ver

Calculation of Filing Fee Tables FORM S-8 (Form Type) ARTIVION, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) ARTIVION, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 ARTIVION, INC. (Exact name of registrant as specified in its charter) _____

S-8 1 forms-82023.htm S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1655 Roberts Boulevard, N.W., Ken

Artivion, Inc. Conflict Minerals Report For the reporting period January 1, 2022 to December 31, 2022

Exhibit 1.01 Artivion, Inc. Conflict Minerals Report For the reporting period January 1, 2022 to December 31, 2022 Background This Conflict Minerals Report (the “Report”) of Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”) has been prepared pursuant to Rule 13p-1 and Form SD (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ___________________________________________ ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-241709

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144 (Address of principal executive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2023 ARTIVION, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2023 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number)

ARTIVION, INC. 2020 EQUITY AND CASH INCENTIVE PLAN SECTION 1

Exhibit 10.1 ARTIVION, INC. 2020 EQUITY AND CASH INCENTIVE PLAN SECTION 1 GENERAL 1.1 Purpose. The Artivion, Inc. 2020 Equity and Cash Incentive Plan (the “Plan”) has been established by Artivion, Inc. (the “Company”)1 to (i) attract, retain, and reward persons eligible to participate in the Plan; (ii) motivate Participants (as defined in Section 1.2 below), by means of appropriate incentives, to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 o TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2023 ARTIVION, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2023 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Artivion Reports First Quarter 2023 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports First Quarter 2023 Financial Results First Quarter and Recent Business Highlights: •Achieved revenue of $83.2 million in the first quarter of 2023 versus

ANNUAL REPORT TO SECURITY HOLDERS

2022 2022 Annual Report to Stockholders NYSE:AORT www.artivion.com1655 Roberts Boulevard, N.W. Kennesaw, GA 30144 PHONE: (770) 419-3355 FAX: (770) 429-5250 E-MAIL: [email protected] www.artivion.com FORM 10-K Included in this Annual Report to Stockholders is a copy of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, including certifications by the Chief Executi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2

Subsidiaries of Artivion, Inc.

Exhibit 21.1 SUBSIDIARIES OF ARTIVION, INC. Subsidiary Jurisdiction Artivion Colombia SAS Colombia Artivion Cyprus Limited Cyprus Artivion EMEA GmbH Germany Artivion Hellas Single Member Ltd. Greece Artivion Hong Kong, Limited Hong Kong Artivion LATAM Holdings Spain, SLU Spain Artivion Malaysia, Sdn. Bhd. Malaysia Artivion New Zealand New Zealand Ascyrus Medical GmbH Germany Ascyrus Medical LLC Fl

Second Amendment to Exclusive Distribution Agreement, by and between JOTEC GmbH, as distributor, and Endospan Ltd., as manufacturer, dated December 30, 2022. (Incorporated herein by reference to Exhibit 10.21(b) to the Registrant's Annual Report on Form 10-K filed February 23, 2023.)

Exhibit 10.21(b) CERTAIN INFORMATION HAS BEEN OMITTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT NO. 2 TO EXCLUSIVE DISTRIBUTION AGREEMENT This Amendment No. 2 is dated December 30, 2022 (the “Amendment”), and is between JOTEC GmbH, a wholly-owned subsidia

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 ARTIVION, INC. (E

Description of Artivion, Inc.’s Securities under Section 12 of the Exchange Act.

Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, Artivion, Inc., a Delaware corporation (the “Company”), had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): Common Stock. Description of Common Stock The following descri

Second Amendment to Clinical Research Agreement, dated January 20, 2022, by and between Artivion, Inc. and Duke University (Incorporated herein by reference to Exhibit 10.13(b) to the Registrant’s Annual Report on Form 10-K filed February 23, 2023.)

Exhibit 10.13(b) CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Amendment Form Amendment No. 2 Amendment Submission Date: January 20, 2022 Sponsor: Artivion, Inc. (formerly CryoLife, Inc.) Study Title: PROACT Xa - Prospec

Summary of 2022 Compensation Arrangements with Non-Employee Directors.

Exhibit 10.6 SUMMARY OF 2022 COMPENSATION ARRANGEMENTS WITH NON-EMPLOYEE DIRECTORS (Effective as of December 31, 2022) The following summarizes the compensation and benefits received by the non-employee Directors of Artivion as of December 31, 2022. It is intended to be a summary of compensation arrangements, and in no way is intended to provide any additional rights to any non-employee Director.

Fourth Amendment to Credit and Guaranty Agreement between Artivion, Inc. (f/k/a CryoLife, Inc.), the Guarantor Subsidiaries defined therein, the financial institutions party thereto from time to time as lenders, and Deutsche Bank AG New York Branch, as Administrative Agent. (Incorporated herein by reference to Exhibit 10.14(d) to the Registrant’s Annual Report on Form 10-K filed February 23, 2023.)

Exhibit 10.14(d) EXECUTION VERSION FOURTH AMENDMENT TO CREDIT AND GUARANTY AGREEMENT THIS FOURTH AMENDMENT TO CREDIT AND GUARANTY AGREEMENT is dated as of December 19, 2022 (this “Fourth Amendment”), and entered into by and among Artivion, Inc. (f/k/a CryoLife, Inc.), a Delaware corporation (the “Borrower”), the Guarantor Subsidiaries party hereto, the Lenders party hereto and Deutsche Bank AG New

Third Amendment to Clinical Research Agreement, dated November 18, 2022, by and between Artivion, Inc. and Duke University (Incorporated herein by reference to Exhibit 10.13(c) to the Registrant’s Annual Report on Form 10-K filed February 23, 2023.)

Exhibit 10.13(c) CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Amendment Form Amendment No. 3 Amendment Submission Date: November 18, 2022 Sponsor: Artivion, Inc. Study Title: PROACT Xa - Prospective Randomized On-X Anti

Form of 2022 Grant of Non-Employee Director Restricted Stock Award Agreement pursuant to the Artivion, Inc. 2020 Equity and Cash Incentive Plan.

Exhibit 10.3(a) Name: %%FIRSTNAMEMIDDLENAMELASTNAME%-% Total No. of Units: %%TOTALSHARESGRANTED%-% ARTIVION RESTRICTED STOCK AWARD AGREEMENT ARTIVION, INC. (“Artivion”) is pleased to grant you the restricted stock award described below (“Stock Award”). This grant is made subject to the further terms and conditions set forth in this Agreement and the terms of the Artivion, Inc. 2020 Equity and Cash

Artivion Reports Fourth Quarter and Full Year 2022 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Fourth Quarter and Full Year 2022 Financial Results Fourth Quarter and Recent Business Highlights: •Achieved revenue of $79.4 million in the fourth quart

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 16, 2023 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Num

Page 9 of 13

EX-99.A 2 d444901dex99a.htm EX-99.A Exhibit A EXHIBIT A AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS AGREEMENT made this 2nd day of FEBRUARY, 2021 by and between Delaware Funds® by Macquarie listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectively referred to as the “parties”). W

Page 13 of 13

EX-99.B 3 d444901dex99b.htm EX-99.B Exhibit B EXHIBIT B Powers of Attorney for Macquarie Group Limited and Macquarie Bank Limited incorporated by reference to 13G filings made by Macquarie Group Limited and Macquarie Bank Limited on May 25, 2021. Page 13 of 13

AORT / Artivion Inc / MACQUARIE GROUP LTD - SC 13G/A Passive Investment

SC 13G/A 1 d444901dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Artivion Inc (Name of Issuer) Common Shares (Title of Class of Securities) 228903100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th

AORT / Artivion Inc / WASATCH ADVISORS INC Passive Investment

SC 13G/A 1 aort223.txt SCHEDULE 13G Amendment No. 2 Name of Issuer: Artivion, Inc. Title of Class of Securities: Common Stock CUSIP Number: 228903100 Item 1: Reporting Person: Wasatch Advisors LP 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 1,531,707 Item 6: Sha

AORT / Artivion Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0316-artivioninc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Artivion Inc. Title of Class of Securities: Common Stock CUSIP Number: 228903100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule

AORT / Artivion Inc / MORGAN STANLEY - MS INITIAL Passive Investment

SC 13G 1 ArtivionIncAORT.txt MS INITIAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* ARTIVION, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 228903100 - (CUSIP Number) December 30, 2022 - (Date Of Event which Requires Filing of this Statement) Check the appropriate box to desi

AORT / Artivion Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Artivion, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 228903100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat

AORT / Artivion Inc / BlackRock Inc. Passive Investment

SC 13G/A 1 us2289031005012623.txt us2289031005012623.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) ARTIVION, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 228903100 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

AORT / Artivion Inc / BlackRock Inc. Passive Investment

SC 13G 1 us2289031005011923.txt us2289031005011923.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ARTIVION, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 228903100 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2022 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 o TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165

Change of Control Severance Agreement between Artivion, Inc. and John E. Davis, dated August 2, 2022. (Incorporated herein by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed November 4, 2022.)

Exhibit 10.2 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION TO PROTECT PERSONAL PRIVACY ARTIVION, INC. Change of Control Severance Agreement This Change of Control Severance Agreement (this “Agreement”) dated as of the 2nd day of August, 2022 is made and entered into by and between Artivion, Inc., a Delaware corpo

Form of Indemnification Agreement for Non-Employee Directors and Executive Officers. (Incorporated herein by reference to Exhibit 10.1 to Registrant’s Quarterly Report on Form 10-Q filed November 4, 2022.)

Exhibit 10.1 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of August 2, 2022, between ARTIVION, INC., a Delaware corporation (the “Corporation”), and , a resident of the State of (the “Indemnitee”). W I T N E S S E T H WHEREAS, at the request of the Corporation, Indemnitee is an executive officer and/or a member of the board of directors of

Change of Control Severance Agreement between Artivion, Inc. and D. Ashley Lee, dated August 2, 2022 (Incorporated herein by reference to Exhibit 10.4 to Registrant’s Quarterly Report on Form 10-Q filed November 4, 2022.)

Exhibit 10.4 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION TO PROTECT PERSONAL PRIVACY ARTIVION, INC. Change of Control Severance Agreement This Change of Control Severance Agreement (this “Agreement”) dated as of the 2nd day of August, 2022 is made and entered into by and between Artivion, Inc., a Delaware corpo

Change of Control Severance Agreement between Artivion, Inc. and Jean F. Holloway, dated August 2, 2022 (Incorporated herein by reference to Exhibit 10.3 to Registrant’s Quarterly Report on Form 10-Q filed November 4, 2022.)

Exhibit 10.3 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION TO PROTECT PERSONAL PRIVACY ARTIVION, INC. Change of Control Severance Agreement This Change of Control Severance Agreement (this “Agreement”) dated as of the 2nd day of August 2022 is made and entered into by and between Artivion, Inc., a Delaware corpor

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2022 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Artivion Reports Third Quarter 2022 Financial Results

EX-99.1 2 aort-2022x8k93022ex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Third Quarter 2022 Financial Results Third Quarter and Recent Business Highlights: •Achieved revenue of $76.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 26, 2022 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Elizabeth Hoff Joins Artivion Board of Directors

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Elizabeth Hoff Joins Artivion Board of Directors ATLANTA, GA ? (September 29, 2022) ? Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused

AORT / Artivion Inc / Juniper Investment Company, LLC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Artivion, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 228903100 (CUSIP Number) John A. Bartholdson Juniper Investment Company, LLC 555 Madison Avenue, 24th Floor New York, New York 10022 (212) 339-8500 (Name, Address and Telephone Num

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 23, 2022 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial Study Was Evaluating the Use of Apixaban in Patients Treated with Mechanical Aortic Valves

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President & Phone: 631-807-1986 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial Study Was Evaluating the Use of Apixaban in Patients Treated with Mechanical Aortic Valves ATLANTA, GA -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 o TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTIV

Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2022 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2022 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number

Artivion Reports Second Quarter 2022 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Second Quarter 2022 Financial Results Second Quarter and Recent Business Highlights: ?Achieved revenue of $80.3 million in the second quarter 2022 versus

Artivion, Inc. Conflict Minerals Report For the reporting period January 1, 2021 to December 31, 2021

Exhibit 1.01 ? Artivion, Inc. Conflict Minerals Report For the reporting period January 1, 2021 to December 31, 2021 ? Background This Conflict Minerals Report (the ?Report?) of Artivion, Inc. (?Artivion,? the ?Company,? ?we,? or ?us?) has been prepared pursuant to Rule 13p-1 and Form SD (the ?Rule?) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period Januar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ARTIVION, INC. (Exact name of registrant as specified in its charter) _________________________

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD ? Specialized Disclosure Report ARTIVION, INC. (Exact name of registrant as specified in its charter) ? ? Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) ? 1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144 (Address of principal

 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 ARTIVION, INC. (Exact name of registrant as specified in its charter) ___

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARTIVION, INC. (Exact name of registrant as specified in its charter) ? Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) ? 1655 Roberts Boulevard, N.W. Kennesaw, Georgia 3014

Calculation of Filing Fee Tables Form S-8 (Form Type) ARTIVION, INC. (Exact Name of Registrant as Specified in its Charter)

Exhibit 107 Calculation of Filing Fee Tables ? Form S-8 (Form Type) ? ARTIVION, INC.

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ‎Washington, D.C. 20549 ‎ FORM 8-K CURRENT REPORT ‎PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ‎ Date of Report (Date of earliest event reported): May 18, 2022 ‎ ARTIVION, INC. (Exact name of registrant as specified in its charter) ‎ Delaware 1-13165 59-2417093 (State or Other Jurisdiction ‎of Incorporation) (Commission Fi

Artivion, Inc. Amended and Restated Employee Stock Purchase Plan. (Incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed May 20, 2022.)

Exhibit 10.1 ARTIVION, INC. AMENDED AND RESTATED EMPLOYEE STOCK PURCHASE PLAN ? May 19, 2022 ? 1. Purpose. The Artivion, Inc. Amended and Restated Employee Stock Purchase Plan (the ?Plan?) is intended to encourage employee stock ownership by offering employees of Artivion, Inc. and its subsidiaries Purchase Rights (as such term is defined in Section 2 hereof) to purchase shares of Common Stock. Th

Form of Non-Qualified Stock Option Grant Agreement pursuant to the Artivion, Inc. Equity and Cash Incentive Plan Option Award Agreement. (Incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed May 6, 2022.)

Exhibit 10.1 Artivion, Inc. 1655 Roberts Boulevard N.W. Kennesaw, Georgia 30144 Date of Grant: Name: Address: Re:Grant of Non-Qualified Stock Option Dear This letter sets forth the agreement (the ?Agreement?) between you (?Employee?) and Artivion, Inc., a Delaware corporation (the ?Company?), regarding your option to acquire shares of the Company?s Common Stock. 1.Grant of Option. Subject to the t

Form of Restricted Stock Unit Award Agreement pursuant to the Artivion, Inc. Equity and Cash Incentive Plan. (Incorporated herein by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q filed May 6, 2022.)

Exhibit 10.3 Name: Total No. of Units: ARTIVION, INC. EQUITY AND CASH INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Artivion, Inc. Equity and Cash Incentive Plan (the ?Plan?) will have the same defined meanings in this Restricted Stock Unit Award Agreement, including the Notice of Restricted Stock Unit Grant (the ?Notice of Grant?) a

FORM 10-Q TABLE OF CONTENTS Part I – FINANCIAL INFORMATION Business and Economic Risks Operational Risks Industry Risks Legal, Quality, and Regulatory Risks Risks Relating to Our Indebtedness Risks Related to Ownership of our Common Stock

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTIVION, INC. (Exact

Form of PSU Award Agreement pursuant to the Artivion, Inc. Equity and Cash Incentive Plan. (Incorporated herein by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed May 6, 2022.)

Exhibit 10.2 Name: Total No. of Units: ARTIVION, INC. EQUITY AND CASH INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Artivion, Inc. 2020 Equity and Cash Incentive Plan (the ?Plan?) will have the same defined meanings in this Performance Share Award Agreement, including the Notice of Stock Unit Grant (the ?Notice of Grant?) and the Terms a

Form of Special PSU Award Agreement pursuant to the Artivion, Inc. Equity and Cash Incentive Plan. (Incorporated herein by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q filed May 6, 2022.)

Exhibit 10.4 Name: Total No. of Units: ARTIVION, INC. EQUITY AND CASH INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Artivion, Inc. 2020 Equity and Cash Incentive Plan (the ?Plan?) will have the same defined meanings in this Performance Share Award Agreement, including the Notice of Stock Unit Grant (the ?Notice of Grant?) and the Terms a

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): May 5, 2022 ? ARTIVION, INC. (Exact name of registrant as specified in its charter) ? Delaware 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commission Fil

Artivion Reports First Quarter 2022 Financial Results Achieved revenue of $77.2 million in the first quarter 2022 versus $71.1 million in the first quarter of 2021, an increase of 8.6% on a GAAP basis and 11.2% on a non-GAAP constant currency basis

Exhibit 99.1 ? FOR IMMEDIATE RELEASE ? Contacts: Phone: 770-419-3355 / Lynn Lewis ? Artivion D. Ashley Lee Executive Vice President & Chief Financial Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 332-895-3222 [email protected] ? Artivion Reports First Quarter 2022 Financial Results ? Achieved revenue of $77.2 million in the first quarter 2022 versus $71.1

1655 ROBERTS BOULEVARD, NW KENNESAW, GEORGIA 30144 NOTICE OF ANNUAL MEETING AND PROXY STATEMENT

ARTIVION, INC. | 2022 Proxy Statement ? ? 1655 ROBERTS BOULEVARD, NW KENNESAW, GEORGIA 30144 NOTICE OF ANNUAL MEETING AND PROXY STATEMENT April 4, 2022 To Our Stockholders: On behalf of the Board of Directors, we invite you to attend the Annual Meeting of Stockholders of Artivion, Inc. on May 18, 2022 at 9:00 a.m., EDT. Due to the continuing health and safety concerns from the COVID-19 pandemic an

ANNUAL MEETING OF STOCKHOLDERS OF May 18, 2022 PROXY VOTING INSTRUCTIONS

ANNUAL MEETING OF STOCKHOLDERS OF May 18, 2022 PROXY VOTING INSTRUCTIONS INTERNET - Access ?www.

Item 1A. Risk Factors. Business and Economic Risks Operational Risks Industry Risks Legal, Quality, and Regulatory Risks Risks Relating to Our Indebtedness Risks Related to Ownership of our Common Stock Aortic Stents and Stent Grafts On-X

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 ARTIVION, INC. ?(

Summary of 2021 Compensation Arrangements with Non-Employee Directors.

Exhibit 10.6 SUMMARY OF 2021 COMPENSATION ARRANGEMENTS WITH NON-EMPLOYEE DIRECTORS (Effective as of December 31, 2021) ? The following summarizes the compensation and benefits received by the non-employee Directors of Artivion as of December 31, 2021. It is intended to be a summary of compensation arrangements, and in no way is intended to provide any additional rights to any non-employee Director

Subsidiaries of Artivion, Inc.

Exhibit 21.1 SUBSIDIARIES OF ARTIVION, INC. ? ? Subsidiary Jurisdiction Ascyrus Medical GmbH Germany Ascyrus Medical LLC Florida AuraZyme Pharmaceuticals, Inc. Florida CryoLife Asia Pacific, PTE. Ltd Singapore CryoLife Beijing Medical Device Ltd. China CryoLife Canada, Inc. Canada CryoLife Europa, Ltd. England and Wales CryoLife France, SAS. France CryoLife Germany HoldCo GmbH. Germany CryoLife Ge

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): February 17, 2022 ? ARTIVION, INC. (Exact name of registrant as specified in its charter) ? Delaware 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commissi

Artivion Reports Fourth Quarter and Full Year 2021 Financial Results

Exhibit 99.1 ? FOR IMMEDIATE RELEASE ? Contacts: ? ? Artivion D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 332-895-3222 [email protected] ? ? Artivion Reports Fourth Quarter and Full Year 2021 Financial Results ? Fourth Quarter and Recent Business Highlights: ? Achieved re

CRY / Cryolife Inc / MACQUARIE GROUP LTD - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Artivion Inc (Name of Issuer) Common Shares (Title of Class of Securities) 228903100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

CRY / Cryolife Inc / WASATCH ADVISORS INC Passive Investment

SCHEDULE 13G Amendment No. 1 Name of Issuer: Cryolife Inc. Title of Class of Securities: Common Stock CUSIP Number: 228903100 Item 1: Reporting Person: Wasatch Advisors, Inc. 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 2,788,702 Item 6: Shared Voting Power: 0 I

CRY / Cryolife Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: CryoLife Inc. Title of Class of Securities: Common Stock CUSIP Number: 228903100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule

CRY / Cryolife Inc / BlackRock Inc. Passive Investment

us2289031005012722.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) CRYOLIFE INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 228903100 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

CRY / Cryolife Inc / BlackRock Inc. Passive Investment

us2289031005012522.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) CRYOLIFE INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 228903100 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

CryoLife Announces Corporate Rebranding and Changes Name to Artivion Artivion to Host Investor & Analyst Day on March 23, 2022

Exhibit 99.1 ? ? FOR IMMEDIATE RELEASE Contacts: ? ? 631-807-1986 CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 [email protected] ? CryoLife Announces Corporate Rebranding and Changes Name to Artivion ? Artivion to Host Investor & Analyst Day on March

Delaware Certificate of Amendment of Certificate of Incorporation, effective January 18, 2022. (Incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed January 20, 2022.)

EX-3.1 2 cry-20220118xex31.htm EX-3.1 Exhibit 3.1  STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION  CryoLife, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows:  1. That the following resolution was duly adopted by unanimous written consen

Amended and Restated Bylaws of Artivion, Inc., a Delaware Corporation (Incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed January 20, 2022

Exhibit 3.2 ? BYLAWS OF Artivion, Inc. (A DELAWARE CORPORATION) ? ARTICLE I OFFICES ? Section 1. Principal and Business Offices. The corporation may have such principal and other business offices, either within or without the State of Delaware, as the Board of Directors (the ?Board?) may from time to time determine or the business of the corporation may require. The corporation?s principal office

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): January 18, 2022 ? ARTIVION, INC. (Exact name of registrant as specified in its charter) ? Delaware 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 CryoLife, Inc. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-A/A ? (Amendment No. 1) ? FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ? CryoLife, Inc. (Exact name of registrant as specified in its charter) ? ? Delaware 59-2417093 (State of incorporation or organization) (I.R.S. Employer Identification No

BYLAWS CRYOLIFE, INC. (A DELAWARE CORPORATION)

Exhibit 3.3 BYLAWS OF CRYOLIFE, INC. (A DELAWARE CORPORATION) ? ARTICLE I OFFICES ? Section 1. Principal and Business Offices. The corporation may have such principal and other business offices, either within or without the State of Delaware, as the Board of Directors (the ?Board?) may from time to time determine or the business of the corporation may require. The corporation?s principal office is

Plan of Conversion, effective January 1, 2022. (Incorporated herein by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed January 4, 2022.)

Exhibit 2.1 PLAN OF CONVERSION FOR CONVERTING CRYOLIFE, INC., a Florida corporation TO CRYOLIFE, INC., a Delaware corporation ? This Plan of Conversion (together with all of the exhibits attached hereto, this ?Plan?), effective January 1, 2022, is hereby adopted by CryoLife, Inc., a Florida corporation (the ?Corporation?), in order to set forth the terms, conditions, and procedures governing the c

Articles of Conversion Florida Profit Corporation Non-Florida Business Entity

Exhibit 3.4 Articles of Conversion For Florida Profit Corporation Into Non-Florida Business Entity ? These Articles of Conversion are submitted to convert the following Florida Profit Corporation into a Delaware Profit Corporation in accordance with Section 607.11933 of the Florida Business Corporation Act (the ?FBCA?). ? 1. The name of the Florida Profit Corporation converting into the resulting

Certificate of Incorporation, effective January 1, 2022. (Incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed January 4, 2022.)

Exhibit 3.2 CERTIFICATE OF INCORPORATION OF CRYOLIFE, INC. ? I, the undersigned, for the purposes of incorporating and organizing a corporation under the General Corporation Law of the State of Delaware (?DGCL?), do execute this certificate of incorporation and do hereby certify as follows: ? ARTICLE I NAME ? The name of the corporation shall be CryoLife, Inc. ? ARTICLE II EXISTENCE OF CORPORATION

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): January 1, 2022 ? CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Delaware 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commission

STATE OF DELAWARE CERTIFICATE OF CONVERSION FROM A NON-DELAWARE CORPORATION TO A DELAWARE CORPORATION PURSUANT TO SECTION 265 OF THE DELAWARE GENERAL CORPORATION LAW

Exhibit 3.1 STATE OF DELAWARE ? CERTIFICATE OF CONVERSION FROM A NON-DELAWARE CORPORATION TO A DELAWARE CORPORATION PURSUANT TO SECTION 265 OF THE DELAWARE GENERAL CORPORATION LAW ? 1.The jurisdiction where the Non-Delaware Corporation was first incorporated, and immediately prior to filing this Certificate of Conversion, is the State of Florida. ? 2.The date on which the Non-Delaware Corporation

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 16, 2021 CRYOLIFE, INC. (Exact name of registrant as specified in its charter) Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File

FORM 10-Q TABLE OF CONTENTS Part I – FINANCIAL INFORMATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 CRYOLIFE INC. (Exa

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): November 4, 2021 ? CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commission

CryoLife Reports Third Quarter 2021 Financial Results

Exhibit 99.1 ? FOR IMMEDIATE RELEASE ? Contacts: Phone: 770-419-3355 / Lynn Lewis ? CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 [email protected] ? CryoLife Reports Third Quarter 2021 Financial Results ? Third Quarter and Recent Business Highlights:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): September 20, 2021 ? CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commissi

N E W S R E L E A S E

EX-99.1 2 cry-20210920xex991.htm EX-99.1 Exhibit 99.1  N E W S R E L E A S E  FOR IMMEDIATE RELEASE  Contacts:  CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer, and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 [email protected]   Anthony Semedo Joins CryoLife Board of Directors   ATLANTA, GA –

 As filed with the Securities and Exchange Commission on August 11, 2021

? ? As filed with the Securities and Exchange Commission on August 11, 2021 Registration No.

Third Amendment to Credit and Guaranty Agreement between Artivion, Inc. and Deutsche Bank AG New York Branch as administrative agent and collateral agent, dated June 2, 2021. (Incorporated herein by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q filed July 30, 2021.)

Exhibit 10.1 THIRD AMENDMENT TO CREDIT AND GUARANTY AGREEMENT THIS THIRD AMENDMENT TO CREDIT AND GUARANTY AGREEMENT is dated as of June 2, 2021 (this ?Third Amendment?), and entered into by and among CryoLife, Inc., a Florida corporation (the ?Borrower?), the Guarantor Subsidiaries party hereto, the Lenders party hereto and Deutsche Bank AG New York Branch, as Administrative Agent. RECITALS: WHERE

FORM 10-Q TABLE OF CONTENTS Part I – FINANCIAL INFORMATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 CRYOLIFE INC. (Exact na

Asset Purchase Agreement dated July 28, 2021, by among Artivion, Inc., and Baxter Healthcare Company. (Incorporated herein by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed July 29, 2021.)

Exhibit 2.1 Execution Copy ASSET PURCHASE AGREEMENT between CRYOLIFE, INC. and BAXTER HEALTHCARE CORPORATION DATED AS OF JULY 28, 2021 ? TABLE OF CONTENTS Page ? Article I DEFINITIONS AND TERMS 1 ? Section 1.1. Definitions 1 Section 1.2. Other Definitional Provisions 9 ? Article II PURCHASE AND SALE 9 ? Section 2.1. Purchase and Sale of Assets 9 Section 2.2. PMAs 9 Section 2.3. Excluded Assets 10

CryoLife Announces Sale of PerClot to Baxter

Exhibit 99.2 FOR IMMEDIATE RELEASE Contacts: ? ? CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 [email protected] ? CryoLife Announces Sale of PerClot to Baxter Atlanta, GA ? (July 29, 2021) ? CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular s

CryoLife Reports Second Quarter 2021 Financial Results

Exhibit 99.1 ? FOR IMMEDIATE RELEASE ? Contacts: Phone: 770-419-3355 / Lynn Lewis ? CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 [email protected] ? CryoLife Reports Second Quarter 2021 Financial Results ? Second Quarter and Recent Business Highlights

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): July 29, 2021 ? CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commission Fi

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): June 2, 2021 ? CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report CRYOLIFE, INC. (Exact name of registrant as specified in its charter)

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD ? Specialized Disclosure Report CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144 (Address of principal execu

CryoLife, Inc. Conflict Minerals Report For the reporting period January 1, 2020 to December 31, 2020

Exhibit 1.01 CryoLife, Inc. Conflict Minerals Report For the reporting period January 1, 2020 to December 31, 2020 ? Background ? This Conflict Minerals Report (the ?Report?) of CryoLife, Inc. (?CryoLife,? the ?Company,? ?we,? or ?us?) has been prepared pursuant to Rule 13p-1 and Form SD (the ?Rule?) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period Januar

Submission of Matters to a Vote of Security Holders

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2021 CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Num

Third Amendment to Lease Agreement between Artivion, Inc. and The H.N. and Frances C. Berger Foundation, successor in interest to P&L Barrett, L.P., dated May 10, 2020. (Incorporated herein by reference to Exhibit 10.15(d) to the Registrant’s Quarterly Report on Form 10-Q filed April 30, 2021.)

Exhibit 10.15(d) CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ? THIRD AMENDMENT TO LEASE ? This Third Amendment to Lease ("Third Amendment'') is entered into by and between THE H.N. AND FRANCES C. BERGER FOUNDATION, a D

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 CRYOLIFE INC. (Exact n

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): April 29, 2021 ? CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commission F

CryoLife Reports First Quarter 2021 Financial Results

Exhibit 99.1 ? FOR IMMEDIATE RELEASE ? Contacts: Phone: 770-419-3355 / Lynn Lewis ? CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 [email protected] ? CryoLife Reports First Quarter 2021 Financial Results ? First Quarter and Recent Business Highlights:

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): March 29, 2021 ? CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commission F